Toxic Leukoencephalopathy following Fludarabine-Associated Hematopoietic Cell Transplantation  by Beitinjaneh, Amer et al.
REVIEWFrom the 1
of Rad
Financial d
Correspon
Divisi
and T
Minn
Received J
 2011 Am
1083-8791
doi:<
300Toxic Leukoencephalopathy following Fludarabine-
Associated Hematopoietic Cell Transplantation
Amer Beitinjaneh,1 Alexander M. McKinney,2 Qing Cao,1 Daniel J. Weisdorf1Toxic leukoencephalopathy has been more thoroughly investigated during the last decade because of the
advance of magnetic resonance imaging (MRI) techniques. We analyzed fludarabine (Flu)-associated hemato-
poietic cell transplantation (HCT), resulting in severe leukoencephalopathy (n 5 39/1596, 2.4%), and
describe 3 clinical syndromes with unique clinical and radiographic characteristics. Posterior reversible
encephalopathy syndrome (PRES) presents predominantly with seizures, persistent headache, and vision
changes, along with variable mental status alterations. PRES is likely to be reversible, particularly after with-
holding cyclosporine (CsA). Acute toxic leukoencephalopathy (ATL) presents with cognitive dysfunction,
decreased levels of consciousness, and vision changes. Other leukoencephalopathy (OLE) includes patients
who behave similar to the ATL group, but with less prominent deep white matter changes on MRI. ATL and
OLE are less likely to be reversible. The neurologic syndromes correlate with different MRI patterns. In PRES,
subcortical and cortical involvement on MRI is associated with seizure, blurred vision, and dysarthria versus
ATL and OLE, which involve deep white matter and cause mainly cognitive dysfunction. The different syn-
dromes also carry different prognoses. All patients with Flu-associated encephalopathy had a median overall
survival of only 169 days. Those with ATL had shorter overall survival (median 66 days) than patients with
PRES (median 208 days). Potential risk factors for Flu-associated encephalopathy were older age, poor renal
function, Flu dose, previously treated central nervous system (CNS) disease, or previous Flu-based trans-
plant conditioning. Additional risk factors for PRES CNS toxicity are CsA use and acute hypertension. Flu
pharmacokinetic studies may be useful to reduce life-threatening Flu-associated risks of neurotoxicity.
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reversible encephalopathy syndromeINTRODUCTION
Hematopoietic cell transplantation (HCT) is the
only curative therapy for many patients with both
malignant and nonmalignant hematologic diseases.
Central nervous system (CNS) toxicity after HCT is
an uncommon, but serious, cause of treatment-related
mortality (TRM). Various studies have estimated the
incidence of severe post-HCT neurologic complica-
tions between 7% and 20% [1-4], often with high
mortality [5]. Neurological complications may include
stroke, hemorrhage, infection, vasculitis, malignancy,Blood andMarrowTransplant Program; and 2Department
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/$36.00plus metabolic or toxic effects of the HCT preparative
regimen [2].
Chemotherapy-induced leukoencephalopathy (LE)
(white matter structural alteration) is more apparent or
at leastmore often recognized in the last decade because
of the advance of magnetic resonance imaging (MRI)
techniques. OnMRI, 2 main patterns of chemotherapy
and immunosuppressive-related LE have been de-
scribed including posterior reversible encephalopathy
syndrome (PRES) and acute toxic leukoencephalopathy
(ATL) [6,7]. LE patterns are based mainly on anatomic
distribution of the white matter (WM) lesions and
different MRI findings. Classical PRES starts from
subcortical WM (SCWM), whereas ATL starts from
periventricular WM (corona radiata and centrum
semiovale) [6,7].
HCT is a complex procedure that may include
total body radiation (TBI), cytotoxic chemotherapy,
and extended pharmacologic immunosuppression.
HCT is performed on patients after previous extensive
therapy sometimes including CNS-directed cranial ra-
diation and intrathecal therapy. Calcineurin inhibitors
(CNI; cyclosporine [CsA] or tacrolimus) and
Biol Blood Marrow Transplant 17:300-308, 2011 301Toxic Leukoencephalopathy following Fludarabine-Associated HCTfludarabine (Flu) can cause severe neurotoxicity. We
hypothesized that these agents contribute to neurotox-
icity during HCT. CNI therapy is associated with
PRES, whereas Flu is associated with PRES and
ATL in early phase I/II trials and case reports [8-12].
Many published case series describe CsA-related
PRES in the setting of HCT, but Flud-related neuro-
toxicity in the setting of HCT is not well described.
Flud may cause dose-related CNS toxicity, and, in
April 2009, the FDA revised its safety labeling
concerning severe CNS toxicity to include widely
used, standard dose of Flu (25 mg/m2  5 days). We
reviewed our experience with Flu-based HCT and
severe LE. We report that Flu-related neurotoxicity
in HCT patients is a clinical syndrome with unique
clinical and radiographic characteristics.MATERIALS AND METHODS
Case Definition and Patient Selection
We prospectively recorded all severe adverse events
for all HCT patients in the University of Minnesota
Blood and Marrow Transplant Database. National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 3.0 grade 3
neurotoxicity includes any neurologic adverse event
that interferes with daily function including weakness,
sensory, behavioral, speech impairment, depressed level
of consciousness, or pyramidal tract dysfunction (eg, in-
creased muscle tone, hyperreflexia, positive Babinski)
[13]. Seizures are considered grade 2 or higher; hence,
all seizure events were reported.We reviewed the insti-
tutional HCT database and hospital records of all
patients receiving Flu-based HCT between 1/2000
and 11/2007 who had severe neurologic adverse events
(ie, NCI CTCAE grade 3 or seizure). The case defini-
tion used to select cases of interest was largely based on
previously reported CNS toxicity seen with early use
of high-dose single-agent Flu in leukemia [8]. The
reported neurotoxicity of Flu is late onset; 1 week to
a few months after Flu administration. Predominant
symptoms can be seizure, cognitive dysfunction, paral-
ysis, decreased vision, and coma in severe cases. Many
patients in those early reports had CT scan or MRI
that showed extensive white matter changes. From
our database review, cases were excluded if neurologic
symptoms were related to peripheral neuropathy,
CNS infection, intracranial bleeding, stroke, CNS
malignancy, sedative medication effect, or metabolic
disturbance (eg uremia, liver failure, and hypoxia).
For each suspected case of Flu-associated neurotox-
icity, we collected the following demographic variables;
age, sex, body surface area, baseline creatinine clear-
ance, type of HCT, indication for HCT, pretransplant
therapies with cranial radiation, intrathecal therapy,
and previous HCT. We also reviewed the Flu dose inthe pre-HCT conditioning, previous exposure to Flu,
and the time between Flu infusion and the development
of CNS symptomatology.
Neurologic symptoms at presentation were sei-
zures, unresolved confusion, unexplained new cogni-
tive dysfunction (mainly memory and word-finding
difficulty), dysarthria, aphasia, paralysis, focal sen-
sory deficit, severe constant headache (.48 hours),
severe depression (required more than 1 antidepres-
sive medication), decreased vision that was unex-
plained by a retinal examination. We recorded the
time to reach a plateau of symptom evolution or
resolution. We reviewed all available biochemicals
(electrolyte, acid base, liver function test, ammonia
level, oxygen saturation) around the time of neuro-
logic symptoms onset. To rule out infectious etiol-
ogy for the mental status changes, we reviewed
microbiology and virology results, and CSF analysis.
We reviewed CsA levels during the 3 weeks prior to
symptom onset. CsA induced PRES may be revers-
ible with discontinuation of CsA or treatment of
hypertension; thus, we recorded the clinical neuro-
logic response to stopping CsA, and we noted any
change of mean blood pressure .25% at the time
of symptoms onset. We also reviewed any recorded
neurologic examination (including consulting neuro-
logic or psychiatric evaluations) plus MRI, EEG,
CT scan, and EMG (when available).
As ATL is a recent and evolving concept and our
older MRI reports did not utilize this terminology, all
neuroimaging was reviewed by a neuroradiologist
(A.M.) with expertise in toxic LE while blinded to
the clinical symptoms and previous neuroradiology
interpretations. The MRI findings were reported on
fluid-attenuated inversion recovery (FLAIR) and
diffusion-weighted images (DWI) detailing the regions
of involvement, and whether the radiologic impression
was consistent with PRES, ATL, nonspecific periven-
tricular white matter (PVWM), or other abnormalities
(with regions of involvement described) at the time of
the neurologic symptom onset. The severity of these
MRI changes was graded based on the extent of abnor-
mality on FLAIR and DWI, with apparent diffusion
coefficient (ADC)map used to confirm theDWI abnor-
malities. ATLhas diffusion restriction (Figure 1), PRES
usually has normal diffusion scans (except maybe in
severe cases), and other LE (OLE) has normal diffusion
scans (DWI). The severity scores for PRES and
ATL were based on grading systems for each as
described [6,7].
Based on the characteristics of the MRI abnormal-
ities, we were able to divide our cohort into 3 groups;
PRES, ATL, and OLE which include white matter
changes of unknown significance, plus a few unclassifi-
able cases (including 1 with limbic and an other with
pontine involvement). All available autopsies were
reviewed by a neuropathologist.
Figure 1. MRI findings. Two selected cases from our review; PRES (A-C); Bilateral temporal, parietal, occipital, and posterior frontal cortical and subcor-
tical edema is noted on FLAIR images (A-B) rather diffusely with some central sparing (arrows). However, onDWI (C), none of the involved regions in A has
bright signal of reduced diffusion; that is, these areas represent vasogenic rather than cytotoxic edema. ATL (D-F); note the central, periventricular bright
signal (arrows) on FLAIR (D) and on DWI (E), also involving the corpus callosum splenium. The bright signal on DWI (F) was confirmed to be reduced
diffusion on ADC maps (not shown), thought to represent potentially reversible swelling within the myelin sheath versus early cytotoxic edema.
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All patients received GVHD prophylaxis with
CsA-based regimens adjusted for trough whole blood
levels. For the majority of patients, CsA was given
along with mycophenolate mofetil (MMF) from day
23 to 130. Patients received 1 of 4 Flu-containing
HCT conditioning regimens; aplastic anemia (AA) pa-
tients received conditioning including alemtuzumab
30 mg/day  3, Flu 30 mg/m2  5 and melphalan
140mg/m2 1. Fanconi anemia (FA) patients received
Flu 30 mg/m2/day  4, cyclophosphamide (Cy) 10
mg/kg/day  4, TBI 300 cGY, and equine ATG 30
mg/kg. Patients with malignant diseases received
either reduced-intensity conditioning (RIC) or mye-
loablative (MA) conditioning. RIC including Flu 40
mg/m2/day  5, Cy 50 mg/kg/day  1, TBI 200 cGy
(some also received ATG 15 mg/kg/day  3) orbusulfan 2 mg/kg orally twice daily  2, instead of
Cy. MA regimen including Flu 25 mg/m2/day  3,
Cy 60 mg/kg/day  2 and fractionated TBI 1320
cGy over 4 days.
Statistical Analysis
Patient characteristics, clinical findings, and out-
comes were compared between the cohorts with differ-
ent neurologic syndromes. For nonnormally distributed
data, the nonparametric Wilcoxon signed rank test and
Mann-Whitney rank sum testwere used to compare dif-
ferences between groups. One-way analysis of variance
(ANOVA) was used when the data was approximately
normally distributed using the general linear models
procedure (PROC GLM). For categorical data, the
Fisher’s exact test was used. Groups with values of
P # .05 were considered to be statistically significant.
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Analysis System statistical software version 9.1 (SAS
Institute, Inc., Cary, NC).RESULTS
Patient Characteristics
Between January 2000 and November 2007, 1596
(624 adults and 972 children) patients received Flud-
based HCT. From this group, 193 patients had severe
neurologic toxicity. After obtaining institutional
review board approval, we reviewed their database
and medical records in detail. Using a specific case
definition, a cohort of 39 patients with Flu-related
severe CNS toxicity was identified. We excluded 154
patients for different reasons (Figure 2). Thirty-three
had peripheral neurologic signs or symptoms, whereas
121 others had neurotoxicity because of other toxic,
metabolic, pharmacologic, hemorrhagic, or infectious
causes.
The Flu neurotoxicity cohort included 21 men and
18 women (median age, 43 years; range: 3-69 years).
Slightly more patients received umbilical cord blood
(UCB) than sibling or volunteer unrelated donor
(URD) HCT (22 and 17, respectively) for diseases as
shown in Table 1. Conditioning regimens for HCT
were RIC in 22 patients, MA in 6 patients, AA regimen
in 3, and FA regimen in 8 patients. Themedian Flu total
dose during conditioning was 200 mg/m2 (range: 75-
200 mg/m2). Given some published reports suggesting
that previous neurotoxic therapy can be an added risk
factor for neurotoxicity, we reviewed their previous che-
motherapy in detail. We found 3 had received prior Flu
(all during previous HCT conditioning); 8 had prior
high-dose cytarabine, and 9 had methotrexate (MTX).
Five percent had previous cranial radiation, 10% had
previous therapeutic intrathecal (IT) chemotherapy
(either MTX or cytarabine or both), and 23% had
prophylactic IT chemotherapy. Nine had previousFigure 2. Study algorithm for patient selection. *OLE includes cases of
limbic and pontine involvement.HCT: 6 previous autologous HCT and 3 allogeneic
HCT.Apre-HCTbrainMRIwas available in 5 patients
(between 6months to 2 years prior toHCT) and all pre-
HCTMRI findings were normal.
Clinical Symptoms at Presentation
The incidence of severe CNS toxicity associated
with Flu conditioning was 39 of 1596 (2.4%). Most
cases occurred following the RIC and AA/FA regi-
mens, which included higher Flu doses. CNS toxicity
presented approximately 2 months (mean 69 days)
after starting Flu (CI 95%; 44.2-93.4). The neurologic
changes evolved over nearly 1 month to reach a plateau
in severity (95%CI 1.6-6.4 weeks). The most common
presenting symptoms were confusion/somnolence
(30%), generalized seizure (21%), severe persisting
headache (19%), and blurred vision (10%). Other
less common (\7% each) presenting symptoms were
dysarthria, pyramidal tract dysfunction, paralysis, or
memory impairment. Impaired alertness, confusion
(74%), and cognitive dysfunction (41%) became
more noticeable over time.
Cognitive dysfunction similar to previously de-
scribed LE syndromes [14] ranged from memory
impairment, confusion, personality changes, severe de-
pression, or word-finding difficulty to stupor, demen-
tia, aphasia, and coma. Generalized seizure (49%) and
vision loss (44%) (cortical or less commonly optic
neuritis) were common. Other symptoms developing
in 15%-35% of patients were pyramidal tract dysfunc-
tion (positiveBabinski, hyperreflexia, weakness/paraly-
sis), dysarthria/aphasia, focal motor deficits, severe
depression (require combination of antidepressive
therapies), incontinence, and tremors (Table 2).
Fludarabine Neurotoxicity, Cyclosporine,
and Hypertension
At the onset of neurotoxicity, 28% of patients had
hypertension (mean blood pressure (BP) increase
.25%). As hypertension may disrupt cerebral autore-
gulation and cause cerebral edema, this could have con-
tributed to progression of the neurotoxicity. CsA levels
were elevated (.400ng/mL)with the 3weeks preceding
the onset of neurotoxicity in 28% of the patients. In
some patients (36%), the neurologic dysfunction im-
proved following CsA withdrawal, but most (78% of
those) had PRES. Flu neurotoxicity may be exacerbated
by CsA leading to a clinical presentation of PRES. It is
likely that CsA contributed to the neurotoxicity in the
36% of patients who had neurologic improvement after
CsA was held, although the most of those had only
partial improvement after holding CSA.
Diagnostic Workup and Neuropathology
Most patients had an extensive workup to exclude
infections, drug, or metabolic causes of their
Table 1. Patients’ Characteristics
Total PRES ATL Other LE
Number 39 17 11 11
Median age (range)* 43 (3-69) 20 (4-69) 55 (13-64) 42 (3-67)
Male/female 21/18 9/8 5/6 7/4
Diagnosis
Hematologic malignancy 30 9 11 10
Nonmalignant disorders 9 8 0 1
Conditioning regimen
Reduced intensity and aplastic anemia* 25 8 (47%) 9 (82%) 8 (73%)
Fanconi anemia 8 3 (18%) 2 (18%) 3 (27%)
Myeloablative 6 6 (35%) 0 0
Graft source
UCB 22 7 (41%) 8 (73%) 7 (64%)
Marrow/PBSC 17 10 (59%) 3 (27%) 4 (36%)
Previous CNS toxic therapy
Flu* 3 0 3 (27%) 0
HiDAC 8 1 (6%) 3 (27%) 4 (36%)
Methotrexate 9 2 (18%) 2 (18%) 6 (54%)
Cranial irradiation or intrathecal chemotherapy* 6 2 4 0
Previous HCT
Autologous + allogeneic 6+3 1+1 3+2 2+0
Conditioning total flud (mg/m2) (95% CI) 200 (151.1-181.7) 144 (142.2-183.2) 200 (147.4-207.2) 200 (127.5-195.3)
Creatinine clearance (ml/min) median (95% CI) 92 (87.6-114.6) 100.6 (93.1-130.9) 81 (63.3-118.1) 85.3 (68-121)
LE indciates leukoencephalopathy; HCT, hematopoietic cell transplant; UCB, umbilical cord blood; PBSC, peripheral blood stem cell; Flu, fludarabine;
HiDAC, high-dose cytarabine; CI, confidence interval; central nervous system; ATL, acute toxic leukoencephalopathy; PRES, posterior reversible en-
cephalopathy syndrome.
*P < .05.
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formed in 30 patients (77%), and, interestingly, was
normal in 20 despite abnormal corresponding brain
MRI done soon thereafter. Lumbar puncture (LP)
was performed in 22 (57%) and was negative for infec-
tion in all cases. CSF was tested for cell count, cytol-
ogy, gram stain, bacterial culture, fungal stain and
culture, Cryptococcus Ag, viral culture, herpes simplex
virus (HSV), cytomegalovirus (CMV), Epstein-Barr
virus (EBV) in almost all cases and HHV6, JC virus,
and varicella zoster virus (VZV) in many cases. Myelin
Basic Protein (MBP) is usually elevated in a demyelini-
zation process [8] and was tested in 4 patients and was
elevated in all 4. Those 4 patients had negative CSF
test for oligoclonal bands. EEG was tested in 22
(57%) of the patients. All showed diffuse theta and
delta wave slowing as seen in encephalopathy of
many causes. One patient had EEG-documented focal
seizure activity.
Autopsy was performed in 5 patients. One patient
had clinical findings of extensive PRES followed by in-
tracranial bleeding and the autopsy showed extensive
intraparenchymal hemorrhage. Another patient with
PRES who later recovered neurologically, but died
of alveolar hemorrhage had normal neuroanatomy at
autopsy. Three patients had autopsy findings compat-
ible with Flu-neurotoxicity previously described in
literature [15]. One ATL patient with a progressive
neurologic course had severe white matter damage
with axonal spheroids, macrophages, edema, and
mild gliosis, along with long tract degeneration char-
acterized primarily by vacuolization with macrophage
infiltration and gliosis. A second patient with OLE andhippocampal involvement had severe subacute neuro-
nal loss and reactive astrocytosis of hippocampal areas
along with diffuse gliosis of the cerebral cortex and
basal ganglia. The third patient with ATL and a wors-
ening neurologic course had striking encephalopathy
changes involving the cerebral white matter, brain
stem, and spinal cord. The same patient had also dif-
fuse white matter degenerative changes with numerous
macrophages, reactive microglia, perivascular cuffing
of mononuclear cells, and occasional axonal damage.Outcome following Neurotoxicity
Follow-up range for survivors was 37 to 2126 days.
Neurotoxicity associated with Flu therapy led to short
survival: median survival 5.6 months (median: 169
days) and estimated 1-year survival of 43% (Figure 3).
Patients with progressive neurologic symptoms had
significantly shorter 1-year survival (75% versus 11%,
P\ .01). Twenty-two patients died before 12 months
and 1 patient was lost to follow up (censored) at 6.7
months from their transplant; thus, 16 patients survived
the first year after transplant. Six of those 16 patients
eventually died or were lost to follow-up beyond 1
year from their transplant date. Of the 10 patients who
survived, 6 were in complete neurologic remission, 3
had substantial neurologic recovery, and 1 patient had
persistent neurologic deficits. Fourteen patients (36%)
died of the neurologic complication, and all of those
diedduring the 6months followingonset of their neuro-
logic syndrome. All the deaths in the ATL group were
related to neurologic toxicity, whereas only 2 of 8 death
cases in the PRES group were related to neurotoxicity.
Table 2. Clinical and Diagnostic Features of Fludarabine-Associated Neurotoxicity
Clinical Syndromes Total PRES ATL Other LE
Total 39 17 11 11
Hypertension* 11 9 (52%) 1 (9%) 1 (9%)
High CsA level 5 (13%) 4 (24%) 1 (9%) 0
Acute GVHD 27 (69%) 12 (71%) 8 (81%) 7 (70%)
Median time to neurotoxicty, days 39 77 31 30
Presenting symptoms
Seizure 8 (21%) 7 (41%) 0 1 (9%)
Headache 7 (19%) 4 (24%) 1 (9%) 2 (18%)
Blurred vision 4 (10%) 1 (5%) 1 (9%) 2 (18%)
Confusion 12 (30%) 2 (12%) 5 (46%) 5 (46%)
Neurologic findings
Seizure* 19 (49%) 14 (82%) 2 (18%) 5 (45%)
pyramidal tract dysfunction* 12 (30%) 1 (5%) 7 (36%) 4 (36%)
Focal deficit 6 (15%) 1 (5%) 1 (9%) 4 (36%)
Cognitive/memory* 16 (41%) 3 (18%) 9 (82%) 4 (36%)
Dysarthria/aphasia 13/6 (33%/15%) 3/1 (18%/5%) 7/4 (64%/36%) 3/1 (27%-9%)
Incontinence* 11 (28%) 0 7 (36%) 4 (36%)
MRI
FLAIR imagines 38 17 11 10
-Mild increase 8 (21%) 3 (18%) 1 (9%) 3 (30%)
-(Moderate + severe) increase 26 (68%) 14 (82%) 10 (58%) 5 (50%)
DWI 36 16 11 10
-Mild decrease 6 (17%) 1 (6%) 5 (46%) 0
-(Moderate + severe) decrease* 9 (25%) 2 (13%) 7 (36%) 0
MRI with contrast 37 16 10 11
-Enhancement 8 (22%) 6 (38%) 0 2 (18%)
CT scan 30 15 5 10
Positive (hypodensities) 10 (33%) 4 (26%) 1 (20%) 4 (40%)
EEG 22 6 9 6
Diffuse slow waves 18 (81%) 6 (100%) 6 (67%) 6 (100%)
Median survival days (95% CI) 169 (28-1483) 208 66 204
Neurotoxcity-related death* 13 (33%) 2 (18%) 8 (73%) 4 (36%)
LE indicates leukoencephalopathy; GVHD, graft-versus-host disease; OS, overall survival; FLAIR, fluid attenuation inversion recovery; DWI, diffusion-
weighted imaging; EEG, electroencephalography; CI, confidence interval; CsA, cyslosporine; ATL, acute toxic leukoencephalopathy, PRES, posterior
reversible encephalopathy syndrome.
*P < .05.
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ing diffuse alveolar hemorrhage (n 5 7), malignant
relapse (n 5 5), multiorgan failure (n 5 1), veno-
occlusive disease (n5 1), and sepsis (n5 1).Figure 3. Srvival after fludarabine CNS toxicity.Neurologic and MRI-Defined Syndromes
The demographics and presentation differed
among the 3 defined syndromes: PRES, ATL, and
OLE. As shown in Table 1, the 3 cohorts were similar
in most demographic characteristics. Patients with
PRES were younger (median age 20 years versus ATL
[median age 55 years] and OLE [median age 42 years]).
RIC and Flu toxicity more often presented as ATL or
OLE (82%), whereas only 41% of PRES had RIC
pre-HCT. Patients with ATL/OLE syndromes were
more likely to have received a higher total dose of
Flu (median 200 mg/m2) than patients with PRES
(175 g/m2 in PRES). Interestingly, patients who devel-
opedATL/OLEweremore likely to have reduced base-
line creatinine clearance compared to PRES patients
(median of 81 mL/min and 85 mL/min versus 101
mL/min for the PRES group). More patients present-
ing with ATL or OLE (versus PRES) had prior Flu
or high-dose cytarabine, and often had previousintrathecal chemotherapy, cranial irradiation, or previ-
ous HCT.
The PRES syndrome was more often associated
with hypertension than the OLE group (52% versus
9%) and high CsA levels .400 ng/mL (24% versus
9%). Additionally, when CsA was discontinued, the
PRES groupweremore likely to have clinical improve-
ment (64% versus 18% and 9% for ATL and OLE)
306 Biol Blood Marrow Transplant 17:300-308, 2011A. Beitinjaneh et al.and less likely to worsen after CsA discontinuation
(17% in PRES versus 64% in ATL). PRES presented
later post-HCT (median 77 days versus 31 days for
ATL and 30 days for OLE. PRES patients more often
had seizures (82%) versus ATL (0%) or OLE (9%).
Pyramidal tract dysfunction, ataxia, cognitive impair-
ment, or incontinence was more frequent in ATL or
OLE than in PRES. Confusion, visual disturbances,
and dysarthria occurred in all 3 groups.
ATL/OLE led to shorter survival compared to
PRES (median 2.2 months versus 6.9 months in
PRES) and more neurologic deaths (64% versus
18%, P \ .05). As shown in Figure 4, those with
ATL/OLE had more frequent progressive neurologic
impairment (73%/64% versus 24% PRES) and infre-
quent neurologic recovery (27%/36% versus 76% in
PRES). None of the ATL patients had complete neu-
rologic recovery, whereas two-third of PRES patients
had complete neurologic recovery.
MRI findings were, to some extent, predictive of
outcome. The intensity of FLAIR and DWI reduction
in MRI with ATL was higher with worse neurologic
course; severe FLAIR and DWI reduction was seen
in 45% who progressed versus only 18% of those
who resolved, however, in PRES the intensity of
FLAIR did not seem to predict a progressive course,
consistent with our previous observation [6]. Patients
with no improvement (clinically or by MRI) within 4
weeks of symptoms onset were unlikely to recover
completely andmore likely to die because of secondary
to the neurologic deficits.DISCUSSION
The pathophysiology of LE following HCT and
Flu therapy is unclear. The clinical syndromes of
PRES and ATL may have different pathophysiology
or might be different presentations of a similar patho-
logic process. Subacute or delayed LE has been de-
scribed with many toxic agents [14] including Flu or
heroin, solvents, cranial irradiation (especially withFigure 4. Neurologic outcomes after fludarabine CNS toxicity.high therapeutic doses) [16], chemotherapies includ-
ing MTX [17,18], 5-FU, and high-dose cytarabine
[19]. Our patients had frequent previous exposure to
methotrexate, cytarabine, and cranial irradiation, al-
though most often months prior to HCT. Although
these exposures could be contributing to this delayed
CNS toxicity, the clinical pattern suggests that prior
CNS toxic exposure may be an added risk for Flu neu-
rotoxicity.
Our observations highlight potentially different
etiologies of the Flu-induced LE clinical syndromes
we observed; PRES, ATL, and OLE. Some have
postulated PRES resulting from reversible capillary
endothelial injury affecting microvascular permeabil-
ity, leading to vasogenic cortical or subcortical white
matter edema [20]. Acute hypertension may induce
PRES, and has been associated with increased sympa-
thetic neural activation. Our patients with PRES were
more likely to have acute hypertension at the time of
the event, more likely to have elevated CsA levels,
and more likely to be reversible compared with other
presentations of LE. Published PRES cases with brain
biopsy demonstrated white matter edema without evi-
dence of fibrinoid necrosis or microinfarction, consis-
tent with theMRI findings of vasogenic edema [21,22].
The tendency of PRES to a posterior localization
(cerebellum and parieto-occipital lobes) and watershed
areas may result from poor sympathetic innervations of
the vertebrobasilar system and thus greater suscepti-
bility to any dysfunction in cerebral vascular autoregu-
lation [23]. The observed clinical associations with
PRES (hypertension, high CSA levels, and potential
reversibility), all highlight a vasogenic cause of the
syndrome; perhaps exaggerating the toxicity of Flu
exposure.
Direct toxic effect on axons, neural progenitor cells,
and oligodendrocytes, and subsequent demyelinization
may all contribute to ATL and may be less often
reversible [7,24,25]. The location of white matter
cerebral injury might be associated with different
neurologic dysfunction from subcortical WM lesions.
Periventricular WM injury may result in more
neurobehavioral dysfunction and mental status changes
[14]. Published reports of autopsy findings in suspected
ATL support a cytotoxic etiology of the syndrome.
Chemotherapy-induced toxic LE usually shows gliosis,
macrophage infiltrate, anddemyelinizationofwhitemat-
ter [7,15,26]. Our 3 patients with ATL onMRI patterns
had autopsy findings consistent with previously
described ATL, where their DWI findings may reflect
water accumulation between myelin lamellae, toxic
demyelination, or oligodendroglial injury.
Interestingly, the condition may improve without
myelin loss, and with improvement of the findings on
FLAIR and DWI MRI [7,27,28]. Although the initial
clinical presentation of ATL and PRES may overlap,
ATL is more likely to present with cognitive
Biol Blood Marrow Transplant 17:300-308, 2011 307Toxic Leukoencephalopathy following Fludarabine-Associated HCTdysfunction and later might progress to incontinence,
ataxia, dementia, and even coma, whereas PRES is
more likely to present with potentially reversible
seizure, motor, and visual changes [6,7].
Both CsA and Flu were associated with PRES. CsA
is reported to be associated with CNS toxicity without
disrupting the blood-brain barrier [29]. It is difficult to
clearly separate CsA-induced PRES from Flu-related
PRES in the context of HCT. Cases with partial clin-
ical improvement following CsA discontinuation may
explain a potential additive toxic effect of CsA and
Flu. Withholding CsA when patients develop PRES
may be advised, but we emphasize the importance of
considering other potential toxicities when symptoms
progress despite discontinuation of CsA. In addition,
controlling blood pressure, electrolyte abnormalities,
fluid overload, and limiting any CNS depressants is
essential. [22,30-32].
Flu is a prodrug that is rapidly dephosphorylated to
the free nucleoside 9-b-Darabinosyl-2-fluoroadenine
(F-ara-A) in erythrocytes and endothelial cells.
F-ARA-A is hydrophilic, and requires concentrative
nucleoside transporters (CNTs) to enter cells. Inside
the cells F-ara-A converted to its active phosphorylated
form that inhibits DNA synthesis and replication.
Different uptake (maybe because of polymorphisms in
CNT3) and different conversion rate might alter its
therapeutic index and risks of toxicity [33]. Flu has
a half life of about 20 hours and it is largely eliminated
by renal excretion (60% during first 24 hours). A
CALGB study, suggested that reduced creatinine
clearance is a risk factor for Flu toxicity [34].Direct neu-
rotoxicity of Flu was observed in preclinical settings
whenmice treatedwith high-dose Flu developed neuro-
logical toxicity12days later, first evident asparesis of the
hind limbs and progressed to ascending paralysis
bilateral and fatal [35]. Early clinical trials with single
agent Flu showed that a Flu dose of 90 mg/m2 for 5
days is associated with 36% incidence of severe CNS
toxicity [8-12], which present similar to our current
observations. In those early trials Flu neurotoxicity
occurred 3 to 8 weeks after the Flu infusion and was
characterized by altered mental status, seizures,
paralysis, and cortical blindness. Autopsies reported in
early Flu phase I/II trials showed varying degrees of
demyelination and necrotizing LE. In the 1990s, the
widely used Flu dose was less than 125 mg/m2 per
cycle and with this lower dose of Flu the incidence of
severe CNS toxicity was substantially decreased (about
0.2%). However, combining Flu with other potential
neurotoxic agents or following prior neurotoxin
exposure increased the risk of neurotoxicity. Patients
with prior high dose cytarabine, intrathecal therapy,
or cranial irradiation may be at greater risk for
neurotoxicity.
Recently, PRES was reported in chronic lumpho-
cytic leukemis (CLL) patients who received Flu doesof only 25 mg/m2 [36]. Group C review suggested
that age over 60 years was a risk factor for CNS toxicity
[37]. With most early reports Flu CNS toxicity, MRI
techniqueswere unable to differentiate distinct patterns
of white matter lesions (ATL versus PRES). The MRI
descriptions were generally limited to scattered exten-
sive white matter disease. Our review suggests brain
MRI with diffusion-weighted imaging (DWI) can add
diagnostic and prognostic information, and may have
prognostic value. Potential risk factors for Flu neuro-
toxicity were older age, renal function, Flu dose,
previousCNS treatment, or a previous Flu-based trans-
plant.Additional risk factors forPRESCNS toxicity are
CsA use and acute hypertension.
Our study has limitations of relatively small size,
and as a case series it is difficult to identify definitive
risk factors. Comparing the PRES group to ATL, we
suggest that progressive neurotoxicity is manifest as
ATL or OLE compared to more reversible toxicity
of PRES. Despite our detailed review, the incidence
of Flu-associated neurotoxicity was possibly underesti-
mated because milder cases were likely unrecognized.
In addition, cases with concurrent CNS abnormalities
(infection, vasculitis, or bleeding) were excluded from
our study.
An HCT procedure is complex, and several con-
founding factors for neurotoxicity need tobe considered
including previous therapy. Nevertheless, our review
supports that Flu CNS toxicity should be considered
in a differential diagnosis of patients with CNS
findings.The poor outcomes associatedwithFlu neuro-
toxicity suggest caution in this drug’s aggressive use,
especially in higher doses. Flu dose reductionmay be in-
dicated in older patients, those with compromised renal
function, and those with previous CNS therapy. Phar-
macokinetic and pharmacogenetic studies may help in
understanding the variability of patients’ response and
toxicity. Well-designed Flu pharmacokinetic studies
may be needed to determine the most appropriate
Flu-dosing to avoid life-threatening neurotoxicity.ACKNOWLEDGMENTS
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